We report here that administration of p38 MAP kinase inhibitor SB203580 in lacrimal glands of a Sjögren’s syndrome mouse model significantly alleviates the dry eye symptom, suggesting the potential clinical implication of SB203580 in the treatment of dry eye in Sjögren’s syndrome. This evidence concerns the gene MAPK14 and Sjogren syndrome.